by Mark Curtis | Oct 20, 2015
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...
by Erin Sugar | Oct 9, 2015
. When he’s not roaming hospital corridors, Dr. Adnan Khera, an anesthesiology resident at Boston’s Tufts Medical Center, can be found dancing on the city streets two nights a week. But he’s not dancing for fame, he’s earning money for his charity “Doctor Be...
by Mark Curtis | Sep 30, 2015
. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a...
by Mark Curtis | Sep 29, 2015
. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...
by Paul Krzyzanowski | Sep 10, 2015
. Bioethicists have had ample time this summer for self-reflection, following Steven Pinker’s op-ed in The Boston Globe that’s informally become known as the “Get out of the way” article. I’ve always found Pinker to be one of my favourite authors due to the fact his...
Comments